Time to revolutionize the triggering of ovulation

Reproductive BioMedicine Online

Volumn 9, Issue 5, 2004, Pages 480-483

  Emperaire, J C ^a   Edwards, R G ^b  

^a Centre FIV   (France)

^b Dry Drayton   (United Kingdom)

Author keywords

Gonadotrophins; Luteal phase; Ovarian hyperstimulation

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE; FOLLITROPIN; GONADORELIN AGONIST; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT LUTEINIZING HORMONE;

ARTICLE; DRUG HALF LIFE; DRUG SAFETY; FEMALE; FEMALE INFERTILITY; FOLLITROPIN RELEASE; HUMAN; LOW DRUG DOSE; LUTEAL PHASE; LUTEINIZATION; LUTEINIZING HORMONE RELEASE; MULTIPLE PREGNANCY; OVARY HYPERSTIMULATION; OVULATION INDUCTION; SINGLE DRUG DOSE; TIME;

EID: 8744233070     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61629-X     Document Type: Note

References (42)

1. Abdallah H, Ah-Moye M 1987 The effect of the dose of HCG and the type of gonadotropin stimulation on oocyte recovery rate. Fertility and Sterility 48, 958-963.
2. Abramov Y, Elchalal U, Schenker JG 1999. An 'epidemic' of severe OHSS: a price we have to pay? Human Reproduction 14, 2181-2185.
3. Asch RH, Li H, Balmaceda JP et al. 1991 Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Human Reproduction 6, 1015-1020.
4. Benadiva CA, Davis O, Kligman I et al. 1997 Withholding gonadotrophin administration is an effective alternative for the prevention of severe ovarian hyperstimulation syndrome. Fertility and Sterility 67, 224-227.
5. Boime I, Fares F, Lapolt PA, Nishimori K, Perlas E, Hsueh AJW 1993 Structure-Function Studies of Gonadotropins Using Site-Directed Mutagenesis and Gene Transfer: Design of a Long-Acting Follitropin Agonist. InGNRH, GNRH Analogs, Gonadotropins and Gonadal Peptides. Parthenon, London, pp.347-356.
6. Brinsden PR, Wada I, Tan SL et al. 1995 Diagnosis, prevention and management of hyperstimulation sydrome. British Journal of Gynaecology and Obstetrics 102, 767-772.
7. Brown JB, Evans JH, Adey FD et al. 1969 Factors involved in the induction of fertile ovulation with human gonadotrophins. Journal of Obstetrics and Gynaecology of the British Commonwealth 76, 298-307.
8. Cohlen BJ, Te Velde ER, Scheffer G et al. 1993 The pattern of the luteinizing hormone surge in spontaneous cycles is related to the probability of conception. Fertility and Sterility 60, 413-417.
9. Crosignani PG, Donini P 1994 The triggering of ovulation with partially desialylated HCG in HMG-stimulated cycles. In: Emperaire JC (ed.) The Triggering of Ovulation in Stimulated Cycles: HCG or LH? Parthenon, London, pp. 99-102.
10. Crosignani PG, Donini P, Lombroso GC et al. 1980 Preparation of a partially desialylated human chorionic gonadotrophin (hCG) and its use for induction of ovulation after ovarian stimulation with human menopausal gonadotrophin. Acta Endocrinologica 95, 232-236.
11. Dahl Lyons CA, Wheeler CA, Frishman GN et al. 1994 Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Human Reproduction 9, 792-799.
12. Edwards RG, Lobo RA, Bouchard P 1996 Time to revolutionize ovarian stimulation. Human Reproduction 11, 917-919.
13. Edwards RG, Lobo RA, Bouchard 1997 Why delay the obvious need for milder forms of ovarian stimulation? Human Reproduction 12 399-401.
14. Emperaire JC, Ruffie A 1991 Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Human Reproduction 6, 506-510.
15. Emperaire JC, Parneix I, Broussin B, Ruffied A 1998 Triggering ovulation with varying doses of human chorionic gonadotropins in stimulated cycles. 54th Annual Meeting of The American Society for Reproductive Medicine, San Francisco 1998. Fertility and Sterility, Abstract Supplement O. 117, p. 75.
16. Emperaire JC, Parneix I, Ruffied A 2004 Luteal phase defects following agonist-triggered ovulation: a patient-dependant response. Reproductive BioMedicine Online 9, 22-27.
17. European Recombinant LH Study Group 1998 Recombinant human luteinizing hormone is as effective as, but safer than, Urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. Journal of Clinical Endocrinology and Metabolism 86, 2607-2618.
18. Faber K 1997 IVF in the US: multiple gestation, economic competition, and the necessity of excess. Human Reproduction 12 1614-1616.
19. Fauser BC, De Jong F, Olivennes F et al. 2002 Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. Journal of Clinical Endocrinology and Metabolism 87, 709-715.
20. Fowler RE, Chat ST H, Walters DE et al. 1977 Steroidogenesis in human follicles approaching ovulation as judged from assays of follicular fluid. Journal of Endocrinology 72, 259-271.
21. Gerris J, Van Royen E 2000 Avoiding multiple pregnancies in ART: a plea for single embryo transfer. Human Reproduction 15 1884-1888.
22. Gordon K 2002 New developments in gonadotrophin pharmacology. Reproductive BioMedicine Online 5, 259-264.
23. Hanssen R 2003 Oral LH agonist: computer-aided molecular design. Gynecological Endocrinology 17 (suppl. 1), 29.
24. Hoff JD, Quigley ME, Yen SSC 1983 Hormonal dynamics at midcycle: a reevaluation. Journal of Clinical Endocrinology and Metabolism 57, 792-796.
25. Hugues JN, Barlow DH, Rosenwaks Z et al. 2003 Improvement in consistency of response to ovarian stimulation with recombinant human follicle stimulating hormone resulting from a new method for calibrating the therapeutic preparation. Reproductive BioMedicine Online 6, 185-190.
26. Jewelewicz R, James SL, Finster M et al. 1972 Quintuplet gestation after ovulation induction with menopausal gonadotropins and pituitary luteinizing hormone. Obstetrics and Gynecology 40, 1-5.
27. Klein J, Lobel L, Pollak S et al. 2003 Development and characterization of a long-acting recombinant hFSH agonist. Human Reproduction 18, 50-56.
28. Ludwig M, Felberbaum RE, Devroey P et al. 2000 Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynaecology and Obstetrics 264, 29-32.
29. Marrs R, Meldrum D, Muasher S et al. 2003 Randomized trial to compare the effect of recombinant FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive BioMedicine Online 8, 175-182.
30. Mathe G 1988 D-Trp-6-LHRH sustained release formulation, a hormonal treatment in prostate cancer, breast cancer and genital dysplasia. Proceedings of the Annual Meeting of the American Society of Clinical Oncologists 7, A 720.
31. Nader S, Berkowitz AS, Maklad N et al. 1986 Characteristics of patients of patients with and without gonadotropin surges during follicular recruitment in an in vitro fertilization/embryo transfer program. Fertility and Sterility 45, 75-78.
32. Navot D, Bergh PA, Lauffer N 1992 Ovarian hyperstimulation syndrome in novel technologies: prevention and treatment. Fertility and Sterility 58, 249-261.
33. Olivennes F, Franchin R, Bouchard P et al. 1996 Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertility and Sterility 66, 151-153.
34. Ruffie A, Emperaire JC, Simonnet C 1994 Effect of triptorelin on gonadotropin secretion during the late follicular phase. In: Emperaire JC (ed.) The Triggering of Ovulation in Stimulated Cycles: HCG or LH? Parthenon, London, pp. 221-226.
35. Rydberg E 1966 The use of pregnant mare's serum and human chorionic gonadotropin in ovarian insufficiency. In: Greenblatt RB (ed.) Ovulation. Lippincott, Philadelphia, pp. 75-90.
36. Shoham Z, Schachter M, Loumaye E et al. 1995 The luteinizing hormone surge - the final stage in ovulation induction: modern aspects of ovulation triggering. Fertility and Sterility 64, 237-251.
37. Tortoriello D, MacGovern P, Cololn J et al. 1998 'Coasting' does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertility and Sterility 69, 454-460.
38. Van Santbrink EJ, Fauser BC 1997 Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens. Journal of Clinical Endocrinology and Metabolism 82, 3597-3602.
39. Vilska S, Tiitinen A, Hyden-Granskog C, Hovatta O 1999 Elective transfer of one embryo results in an acceptable pregnancy rate and eliminates the risk of multiple births. Human Reproduction 14, 2392-2395.
40. White DM, Polson DW, Kiddy D 1996 Induction of ovulation with low dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. Journal of Clinical Endocrinology and Metabolism 81, 3821-3824.
41. Yen SSC, Lenera G, Little B, Pearson OH 1968 Disappearance rate of endogenous luteinizing hormone and chorionic gonadotropin in man. Journal of Clinical Endocrinology and Metabolism 28, 1763-1767.
42. Zelinsky-Wooten MB, Lanzendorf SE, Wolf DP et al. 1991 Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicle. I Oocyte maturation and corpus luteum function. Journal of Clinical Endocrinology and Metabolism 73, 577-583.